Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 27;3(1):vdaa161.
doi: 10.1093/noajnl/vdaa161. eCollection 2021 Jan-Dec.

Clinical correlates for immune checkpoint therapy: significance for CNS malignancies

Nivedita M Ratnam  1 , Stephen C Frederico  1 , Javier A Gonzalez  1 , Mark R Gilbert  1
Affiliations
Review

Clinical correlates for immune checkpoint therapy: significance for CNS malignancies

Nivedita M Ratnam et al. Neurooncol Adv. .

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy. Most commonly, inhibitors of PD-1 and CTLA4 are used having received approval for the treatment of many cancers like melanoma, non-small-cell lung carcinoma, and leukemia. In contrast, to date, clinical studies conducted in patients with CNS malignancies have not demonstrated promising results. However, patients with CNS malignancies have several underlying factors such as treatment with supportive medications like corticosteroids and cancer therapies including radiation and chemotherapy that may negatively impact response to ICIs. Although many clinical trials have been conducted with ICIs, measures that reproducibly and reliably indicate that treatment has evoked an effective immune response have not been fully developed. In this article, we will review the history of ICI therapy and the correlative biology that has been performed in the clinical trials testing these therapies in different cancers. It is our aim to help provide an overview of the assays that may be used to gauge immunologic response. This may be particularly germane for CNS tumors, where there is currently a great need for predictive biomarkers that will allow for the selection of patients with the highest likelihood of responding.

Keywords: CNS malignancies; biomarkers; clinical correlates; immune checkpoint inhibitors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representing select biomarkers both peripheral and intratumoral, proposed for assessment of immune responses of glioblastoma patients treated with immune checkpoint inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. - PubMed
    1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. - PMC - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. - PMC - PubMed
    1. Callahan MK, Horak CE, Curran MA, et al. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J Immunother Cancer. 2013;1(S1):O6.
    1. Reardon DA, Brandes AA, Omuro A, et al. Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003–1010. - PMC - PubMed

LinkOut - more resources